{
    "nctId": "NCT01613482",
    "briefTitle": "TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention",
    "officialTitle": "Interest of the Prophylactic Cerebral Radiotherapy in the Metastatic Breast Cancer Expressing HER2/NEU Treated by Trastuzumab",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Metastasis, Sur-expressing Her2-neu",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 13,
    "primaryOutcomeMeasure": "free of cerebral metastasis survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with breast cancer, expressing HER2-NEU (score +++ in ICH or ++ and amplification on FISH or CISH, SISH)\n* Visceral metastasis, only or multiple\n* First line metastasis treatment by Trastuzumab in association with chemotherapy\n* Good general conditions: OMS=\\<2 or Karnofsky \\>=70%\n* Age \\> 18 years and \\< 70 years\n* Life expectancy \\>=3 mois\n* No Trastuzumab since more of 6 months\n* No cerebral metastasis (MRI)\n* Efficacy contraception for women with genital capacities\n* Consent signed by the patient\n\nExclusion Criteria\n\n* Contraindication to IRM\n* Psychiatric decease\n* Prior cerebral radiotherapy,\n* Geographical constraint, compromising the fallow of patients\n* Infectious or other serious pathology, likely to stop the treatment\n* Positive serology (HIV, hBC, hBS)\n* Inclusion in an other clinical trial or in the 4 weeks before th inclusion\n* Pregnant or breastfeeding women",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}